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We aimed to evaluate the neuroprotective efficacy of rasagiline in pseudophakic patients who had 
surgery for macula-off rhegmatogenous retinal detachment (RRD). This was a 6-month, prospective, 
randomized, double-blind, placebo-controlled pilot study. Patients presenting with acute macula-off 
RRD were recruited and randomized 1:1 to receive rasagiline 1 mg/day or placebo for 7 days. Best-
corrected visual acuity (BCVA) and optical coherence tomography were acquired 1 day before as well as 
2 days, 3 weeks, 3 months and 6 months after surgery. We screened 26 patients with RRD whereof 23 
were eventually included and randomized. The primary outcome was final BCVA. Secondary outcomes 
included central retinal thickness (CRT) and adverse events (AE). We evaluated photoreceptor cells (prc) 
recovery through morphological measurements. The baseline characteristics were comparable between 
groups. BCVA significantly improved in both groups (letters gained: rasagiline 61.5 ± 18.1 vs placebo 
55.3 ± 29.2, p = 0.56), but no significant inter-group difference was found at any visit. CRT was stable 
3 weeks after surgery onwards, with no inter-group difference. No treatment-emergent AE occurred. 
Significant prc restoration was observed from 3 weeks to 6 months after surgery, without inter-group 
difference at either visit. Ellipsoid zone integrity (β = 0.517, p = 0.008) and foveal bulge (β = 0.387, 
p = 0.038) were significant predictors of good final BCVA. In conclusion, perioperative oral treatment 
with rasagiline 1 mg/day for 7 days did not show significant benefits on visual or anatomical outcomes in 
macula-off RRD patients.
Rhegmatogenous retinal detachment (RRD) refers to separation of the neurosensory retina from the retinal pig-
ment epithelium (RPE) due to accumulation of subretinal fluid through one or more retinal breaks1. Currently, 
surgical repair is the only available treatment. Foveal detachment (macula-off) occurs in 54.5% of all RRD 
patients and is a major factor influencing visual recovery after successful surgical repair2.
As a result of deprived metabolic supply from the RPE and choroidal vasculature, photoreceptor (prc) death 
is the ultimate cause of vision loss after RRD3. This is particularly relevant in the macula, where the density of 
prc is the highest and maximal visual acuity is achieved. Arguably, visual acuity recovery is significantly limited 
due to prc loss. Apoptosis was believed to be the major cause involved in prc death. However, recent evidence 
demonstrated that non-apoptotic forms of cell death (autophagy and necrosis), mitochondrial outer membrane 
permeabilization and inflammation raised by the interaction between dying cells and phagocytes all play a role in 
prc death after RRD4. Accordingly, strategies targeting these pathways may be effective in prc rescue after RRD.
Rasagiline [N-propargyl-1-(R)-aminoindan] is a second-generation propargylamine pharmacophore that 
selectively and irreversibly inhibits monoamine oxidase B (MAO-B). It has been an approved drug for the treat-
ment of Parkinson’s disease since the 2000s and mitigates oxidative stress in the brain5. Moreover, rasagiline had 
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neuroprotective potential in preclinical studies that showed that the N-propargyl moiety promotes mitochondrial 
viability and stabilizes permeability transition by regulating Bcl-2 family proteins6.
These findings prompted exploration of the neuroprotective effect of rasagiline in retinal disease. One exper-
imental study assessed prc neuroprotection by rasagiline in Prph2/rds mice, a well-characterized mouse model 
of retinal degeneration. Eigeldinger-Berthou et al. demonstrated that rasagiline not only delayed the activation of 
effector caspases and the subsequent downstream apoptosis, but also affected autophagy induction and inflamma-
tion activity7. Recently, Garcia-Delgado et al. showed rasagiline delayed prc degeneration via modulation of Bax/
Bcl-2 expression in rd10 mice8. Besides, rasagiline enhanced survival of retinal ganglion cells in an experimental 
glaucoma model9 and in a retinal ischemia-reperfusion injury model when it was combined with idebenone10. 
However, no clinical studies have yet investigated the effect of rasageline in patients with RRD.
The standard 1 mg dose of rasagiline in treatment for Parkinson disease has a high safety profile11. The bio-
availability of rasagiline from oral administration was reported to be sufficiently concentrated in the retina in 
mice7. Here, we present the first clinical trial investigating the neuroprotective effects of perioperative oral ras-
agiline (1 mg daily for 7 days) in pseudophakic patients with macula-off RRD.
Methods
Study design and participants. This was a single-center, randomized, double-blind, placebo-controlled 
trial evaluating the neuroprotective effect of rasagiline in patients with macula-off RRD. This study was conducted 
between September 2010 and December 2018 at the Department of Ophthalmology, Bern University Hospital, 
Switzerland. The trial was approved by the local ethics committee, Kantonale Ethikkommission (KEK) Bern 
(approved number, KEK 178/10) as well as the regulatory authority Swissmedic, and registered at ClinicalTrials.
gov (NCT02068625). The study was conducted in accordance with the Declaration of Helsinki. Patients had to 
provide written informed consent before any study specific procedures.
Included participants were adult pseudophakic patients suffering from macula-off RRD with reported central 
vision affection of less than 72 hours at presentation. Exclusion criteria were participation in other clinical trials, 
narrow angle glaucoma, previous intraocular surgery other than cataract operation, any other retinal disease such 
as age-related macular degeneration, concurrent treatment with MAO inhibitors (selective or non-selective), 
pethidine, fluoxetine or fluvoxamine in last 14 days, pregnancy or lactation, malignant arterial hypertension 
(diastolic pressure over 105 mmHg), liver or kidney failure, and any other proximately life-threatening or malig-
nant disease.
Randomization and masking. Randomization took place after informed consent and confirmation that 
inclusion criteria were met. The trial was double-blinded. The study medication, i.e., placebo or rasagiline (Teva 
Pharmaceutical Industries Ltd, Netanya, Israel) was prepared by the Inselspital hospital pharmacy in identical 
pills and stored in neutral vials.
Procedures. Study participants received perioperative oral treatment with either rasagiline (1 mg) or pla-
cebo once daily for 7 days, which was initiated at the time of hospital admission (baseline visit), usually one day 
before planned surgery the next day. Standard 3-port pars plana vitrectomy was performed with 20- or 23-gauge 
instruments, and sometimes an encircling band was added for external support. Hence, the specific choice of the 
detailed surgical procedure was at the discretion of the operating surgeons (S.W., M.S.Z., M.N.M., A.E.). Four 
follow-up visits took place at 2 days, 3 weeks (±5 days), 3 months (±10 days) and 6 months (±10 days) after the 
surgery. At each visit, a thorough ophthalmic exam was completed, including best-corrected visual acuity (BCVA) 
assessed with the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, slit-lamp Goldman applanation 
tonometry, pupil dilation, color fundus photographs including autofluorescence, and spectral-domain Optical 
Coherence Tomography (SD-OCT; Spectralis, Heidelberg Engineering, Germany). Investigators questioned 
patients about medication change or intercurrent adverse events (AE) and instructed patients to report any such 
future events.
Outcomes. The primary outcome was BCVA 6 months after surgical repair. Secondary efficacy outcomes 
were central retinal thickness (CRT) at month 6, measured in the ETDRS grid’s central subfield. Safety endpoints 
included the type and frequency of reported AEs and serious AEs. Additionally, thickness of four different layers 
at week 3 and month 6 (visits 2 and 4) was measured using a commercial software (Orion, Voxeleron LLC, San 
Francisco, USA): ganglion cell complex (GCC), inner nuclear layer-outer plexiform layer complex (INL-OPL), 
outer nuclear layer (ONL) and external limiting membrane (ELM)-RPE. To evaluate prc recovery, we graded the 
integrity of the outer retinal bands, namely ELM, ellipsoid zone (EZ) and cone interdigitation zone (CIZ)12. The 
integrity was graded at the fovea in a 1-mm-diameter area on a 5-point scale as follows: (1) line not visible; (2) line 
disruption >500 μm; (3) line disruption >200 μm, but <500 μm; (4) line disruption <200 μm; (5) continuous 
line. Lastly, we graded the presence of the foveal bulge at the end of the study, an indicator of good foveal micro-
structure. A foveal bulge was defined as an EZ-RPE thickness at the central fovea >10 μm greater than the average 
EZ-RPE thickness at 250 μm temporal and nasal to the central fovea13.
Statistical analysis. Surgical success and failure rates were calculated. The failure rate was expressed in two 
ways14. The primary failure rate was the percentage of eyes that had a recurrent detachment or a complication 
after the initial procedure requiring an additional surgery but no silicone oil. There was a second group of patients 
who developed severe proliferative vitreoretinopathy (PVR) that was managed with silicone oil tamponade left 
in place for at least six months. These eyes had silicone oil remaining at the end of the study and their final visual 
outcomes pending. These eyes were not included in outcome analysis.
Analyses were performed on three sets. The safety set consisted of all randomized participants who took the 
perioperative oral medication for 7 days and underwent at least 1 safety assessment after enrolment. The full 
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analysis set (FAS) consisted of all participants who completed the trial and did not develop PVR managed with 
silicone oil tamponade and had reliable visual acuity data at study end 6 months after initial repair. The uneventful 
set consisted of all randomized participants completing the study without the need for any additional intraocular 
surgery to address complications (Fig. 1).
Continuous data were summarized using mean and standard deviation. We used Student’s t-test to test the 
null hypothesis of no difference between the means of the two randomized groups. Categorical data were summa-
rized using percentages, and the groups were compared using Fisher’s exact test. We constructed linear regression 
models to evaluate the effect of variables on study outcomes. Statistical testing was two-sided with a 5% signifi-
cance level.
Results
Baseline characteristics. A total of 26 participants signed informed consent and entered screening. Three 
participants did not meet inclusion criteria. Hence, the safety set included 23 patients (rasagiline, n = 12; placebo, 
n = 11).
Baseline characteristics were well balanced for demographic parameters, BCVA, and duration of symptoms 
before presentation group (Table 1). The average age was 68.0 ± 10.5 years, 78% were male. There was no signifi-
cant difference between groups for any of the parameters (p > 0.05).
Surgical success rate. SF6 gas tamponade was used in all 23 primary surgeries. In total, 16 participants 
were successfully repaired by single surgery, achieving a single operation success rate (SOSR) of 70% (rasagiline, 
67%; placebo, 73%). Five recurrent detachments (rasagiline, n = 3; placebo, n = 2), one full thickness macular 
hole (FTMH; rasagiline group), and one severe epiretinal membrane (ERM; placebo group) occurred during the 
study period, leading to a primary failure rate of 30%. Two of the re-detachments, one in each arm, received two 
additional surgeries and were excluded from the FAS due to remaining silicone oil and severe PVR at the end of 
study. Thus, the PVR rate was 9%. The other cases were managed by one additional surgery. Therefore, 21 partici-
pants (91%) completed the trial and were included in the FAS (rasagiline, n = 11; placebo, n = 10). 16 participants, 
8 in each arm had an uncomplicated postoperative course, forming the uneventful set. Details of the additional 
surgeries during the study follow-up are listed in Table 2.
Visual outcome. BCVA significantly improved in both groups after surgery (letters gained in 6 months, FAS: 
61.5 ± 18.1 in rasagiline and 55.3 ± 29.2 in placebo group; Uneventful set: 68.8 ± 9.1 in rasagiline and 50.8 ± 30.6 
in placebo group), but there was no significant difference of final BCVA between groups (Rasagiline 74.9 ± 9.1 
letters vs. placebo 72.7 ± 19.5 letters, Table 3). The most significant improvement in BCVA was noted during the 
first three weeks after the surgery (FAS: 43 letters in rasagiline and 36 letters in placebo group; Uneventful set: 51 
letters in rasagiline and 39 letters in placebo group), with no significant difference between groups. There was no 
difference at any visit between the rasagiline and placebo groups in BCVA (Fig. 2). Final BCVA of the two PVR 
cases with silicone oil tamponade in situ were finger counting and 20 letters, respectively. The other eyes requiring 
additional surgery reached a mean final BCVA of 63.8 letters (range: 45–81), and 75% of the eyes had 60 ETDRS 
letters or better BCVA.
Figure 1. Flow diagram of the trial.
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Anatomical outcome. CRT was stable from week 3 to month 6, and there was no difference between the 
rasagiline and placebo groups for the CRT at either visit (FAS: p = 0.6 at week 3, p = 0.9 at month 6; Uneventful 
set: p = 0.2 at week 3, p = 0.9 at month 6, Fig. 3).
Thicknesses of GCC, INL-OPL and ONL were stable from week 3 to month 6, and there was no difference 
between the rasagiline and placebo groups for CRT at either visit (regardless whether in the FAS or in the une-
ventful set (Fig. 4)).
ELM-RPE thickness significantly increased from week 3 to month 6, but there was no difference between 
the rasagiline and placebo groups at either visit, regardless of fovea (ETDRS central 1 mm subfield) or macula 
(ETDRS 6 mm area) (Fig. 5). Table 4 summarizes the grading result related to prc recovery. Integrity of ELM and 
EZ bands significantly improved in both groups without inter-group difference. The placebo group had a slightly 
better CIZ band integrity at week 3 (rank: 1.0 vs 1.1, p = 0.029). The foveal bulge was seen in 6 eyes at month 6 
Rasagiline 
(n = 12)
Placebo 
(n = 11)
Total 
(n = 23)
Age (yrs), mean (SD) 67.2 (9.7) 69.0 (11.7) 68.0 (10.5)
Gender
   Female 3 (25%) 2 (18%) 5 (22%)
   Male 9 (75%) 9 (82%) 5 (78%)
Study eye
   Right 6 (50%) 6 (55%) 12 (52%)
   Left 6 (50%) 5 (45%) 11 (48%)
BCVA
   ETDRS letters, mean (SD) 14.3 (20.2) 19.5 (27.1) 16.8 (23.4)
   ≥30 letters 2 (17%) 4 (36%) 6 (26%)
IOP (mmHg), mean (SD) 13.1 (3.4) 13.2 (4.0) 13.1 (3.6)
Duration vision loss before presentation
   ≤24 hours 3 (25%) 1 (9%) 4 (17%)
   24–72 hours 9 (75%) 10 (91%) 19 (83%)
Current treatment with ASA 4 (33%) 4 (36%) 8 (35%)
Height of macular detachment (μm) 707.0 (307.8) 771.3 (364.8) 739.2 (329.1)
Table 1. Baseline characteristics of the participants in the safety set. Height of macular detachment 
were gradable in 18 participants (9 in each group) in the safety set. BCVA = best-corrected visual acuity, 
ETDRS = Early Treatment Diabetic Retinopathy Study, IOP = intraocular pressure, ASA = acetylsalicylic acid.
Rasagiline 
(n = 12)
Placebo 
(n = 11) P value
Unsuccessful repair 4 (33%) 2 (18%) 0.64
  Recurrence of retinal detachment 3 (25%) 2 (18%) 1
   Time to first recurrence (days), mean (range) 23.0 (18–29) 29.5 (12–47) 0.67
   Number of additional surgery, mean (range) 1.3 (1–2) 1.5 (1–2) 0.79
   Silicone oil endotamponade 2 (67%) 2 (100%) 1
   Proliferative vitreoretinopathy development 1 (33%) 1 (50%) 1
  Full thickness macular hole 1 (8%) — —
   Time to additional surgery (days) 41 — —
  Epiretinal membrane — 1 (9%) —
   Time to the additional surgery (days) — 73 —
Table 2. Additional surgery requirement of the participants in the safety set.
Full analysis set Uneventful set
Rasagiline (n = 11) Placebo (n = 10) P value Rasagiline (n = 8) Placebo (n = 8) P value
ETDRS letters, mean (SD) 74.9 (9.1) 72.7 (19.5) 0.74 76.8 (8.8) 77.5 (18.3) 0.92
≥65 letters 9 (82%) 7 (70%) 0.64 7 (88%) 6 (75%) 1
Gained letters, mean (SD) 61.5 (18.1) 55.3 (29.2) 0.56 68.8 (9.1) 50.8 (30.6) 0.13
Table 3. Final visual acuity at month 6 of the participants in FAS and uneventful set. ETDRS = Early Treatment 
Diabetic Retinopathy Study.
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(29%, 3 eyes in each group). Simple linear regression analysis demonstrated that male gender, EZ integrity and 
presence of foveal bulge are positively correlated with better final BCVA. Multiple stepwise regression analysis 
confirmed EZ integrity and presence of bulge as factors influencing final BCVA. (Table 5)
Safety. A total of 8 participants (35%) reported side effects (Table 6). No serious AE was reported. There 
was no difference in the number of AE or side effects between the groups. Thus, rasagiline was well tolerated in 
patients with RRD.
Discussion
The surgical approach is currently the only means to repair RRDs and preserve or restore vision. However, visual 
outcomes vary, even in patients who have had successful primary surgical repair. Prc death supposedly is the 
ultimate cause of vision loss after a RRD. Therefore, pharmacotherapy reducing or slowing degeneration of prcs 
would be a potential add-on therapy enhancing functional outcomes. Several studies targeting these pathways 
provide evidences that a neuroprotective strategy might potentially result in prc rescue after RRD3,4.
Selegiline [L-deprenyl] is an earlier selective irreversible MAO-B inhibitor used in Parkinson’s disease, and 
showed some neuroprotective effect in retinal cells, such as lower apoptosis and higher viability in cultured RPE 
that led to increased survival of retinal ganglion cells after retinal damage in rats15. Later, rasagiline replaced 
selegiline in the clinic because of 15-fold higher potency. Studies demonstrated that rasagiline influences multi-
ple pathways related to prc death, including Caspase-3 activation and Bax/Bcl-2 expression that are involved in 
apoptosis, while Beclin-1expression is involved in autophagy, and Caspase-1 activation and glial fibrillary acidic 
protein expression are involved in inflammation7,8.
Figure 2. Mean BCVA change during the follow-up of the participants in the FAS and the uneventful set. Mean 
BCVA significantly increased during the observation period in both groups of both sets. Large improvement 
happened during the first 3 weeks. There was no difference at any visit between the rasagiline and placebo 
groups in BCVA (P > 0.05). BL = baseline.
Figure 3. CRT change from week 3 to month 6 of the participants in the FAS and the uneventful set. No 
significant difference in CRT was observed from week 3 to month 6 in both groups of both sets (P > 0.05). There 
was no difference at either visit between the rasagiline and placebo groups (P > 0.05).
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Despite these promising results in the animal model, no pharmacotherapies have been clinically tested yet. 
We, therefore, carried out this clinical pilot trial to evaluate the efficacy of pharmacotherapy as an adjunct to 
surgical RRD repair. This study prospectively assessed rasagiline 1 mg/day treatment for 7 days in pseudophakic 
macula-off RRDs. We found no measurable effect of rasagiline compared to placebo. Our findings thus fell short 
of identifying a clinical neuroprotective effect of rasagiline at this dose on patients who had surgical repair within 
96 hours (maximal time interval between vision loss and presentation plus waiting time to start of operation for 
surgical repair) of onset of symptoms.
Failure of rasagiline to show any neuroprotective effect in our study could be due to several reasons: First, 
the dose tested or the treatment duration might have been insufficient. We decided to apply this conservative 
regimen in the first clinical trial of rasagiline in retinal disease based on two facts: (1) the standard 1 mg dose 
given to Parkinson’s disease patients is well tolerated; (2) 7-day rasagiline administration was regarded as min-
imal duration for treatment16. However, with regard to the treatment dose, the two preclinical studies showing 
neuroprotection of rasagiline on prc used 2 μg/g BW/d in Prph2/rds mice and 15 μg/g BW/d in rd10 mice7,8. This 
would be equivalent to a daily dose of 10 mg and 75 mg for a 60-kg human. These doses are much higher than 
Figure 4. Thickness change of GCC, INL-OPL and ONL from week 3 to month 6 of the participants in the FAS. 
No significant thickness difference in GCC, INL-OPL and ONL was observed from week 3 to month 6 in both 
groups of both sets (P > 0.05). There was no difference at either visit between the rasagiline and placebo groups 
(P > 0.05).
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commonly used in clinic, and the second dosage would even exceed the reported tolerability range in human17. 
With respect to treatment duration, experience from the treatment of Parkinson’s disease suggests that rasagiline 
is limited in efficacy, but has a consistent benefit with chronic administration18. Hence, 7 days of treatment might 
not have been long enough.
Moreover, the follow-up intervals might have been unsuitably defined to evaluate pcr rescue. Differences 
might have been present around the 3 weeks time point. Prc death in human occurred as early as 12 h, peaked at 
around 2–3 days and dropped to low levels by 7 days after RRD19. Meanwhile, rasagiline achieves 80% MAO-B 
inhibition after a single standard dose and increases to 99% after 7-day administration. After treatment with-
drawal, the inhibitive effects decline time-dependently and lasts for utmost 3 weeks20. Taken together, more ben-
efit from neuroprotection might result from faster availability. In addition, Eigeldinger-Berthou et al. stated in 
their preclinical study that prc death was only delayed but not absent after rasagiline treatment7. In our study, prc 
evaluation through OCT images was only available 3 weeks after surgery when the SF6 gas had disappeared from 
the macular area. Therefore, our failure to find difference between groups from 3 weeks to 6 months after surgery 
might be due to bad timing, imposed by technical constraints. Novel in vivo evaluation would be helpful to reveal 
the prc change in the early postoperative phase. Ahn et al. demonstrated that swept-source OCT performed sig-
nificantly better than SD-OCT in macular visualization in gas-filled eyes at days 1 and 3 after surgery21. However, 
their research only focused on the visualization of macular configuration, but not of the outer retinal bands. 
Fluorescence Lifetime imaging ophthalmoscopy (FLIO) might be a promising future option. FLIO measures life-
times of endogenous retinal fluorophores after excitation using a picosecond pulsed blue laser light22. Lipofuscin 
is a major endogenous retinal fluorophore, and accumulates after RPE cells aging, which originates from incom-
plete degradation of prc outer segment23. Therefore, FLIO might be valuable to visualize prc death after RRD. No 
study has covered this topic and further research is needed.
Furthermore, other pathways might outweigh the beneficial effects attributed to rasagiline (i.e., MAO-B inhi-
bition, effects on oxidative stress, mitochondrial dysfunction and antiapoptotic properties) in the context of RRD. 
In addition to prc death, RRD also causes complex cellular remodeling of neuron synapses and Müller cells, 
which hamper visual function and prc regeneration, respectively24. Furthermore, prc survival and death pathways 
are trigged at the same time after detachment, when some mechanism works as a scroll bar pulling prc toward 
Figure 5. ELM-RPE thickness change from week 3 to month 6 of the participants in the FAS. ELM-RPE 
thickness significantly increased from week 3 to month 6 in both groups (p < 0.05). There was no difference 
between the rasagiline and placebo groups at either visit (P > 0.05). *p < 0.05, **p < 0.01.
Rasagiline (n = 11) Placebo (n = 10)
Visit 2 Visit 4 P value Visit 2 Visit 4 P value
ELM band integrity, rank 3.8 4.8 0.002 3.8 4.8 0.001
EZ band integrity, rank 3.3 4.6 <0.001 3.0 4.4 0.001
CIZ band integrity, rank 1.0* 1.5 0.096 1.1* 1.7 0.024
Table 4. Integrity of outer retinal bands at visits 2 (week 3) & 4 (month 6) of participants in FAS. The integrity 
was graded at the fovea in a 1-mm-diameter area on a 5-point scale as follows: (1) line not visible; (2) line 
disruption >500 μm; (3) line disruption >200 μm, but <500 μm; (4) line disruption <200 μm; (5) continuous 
line. *Significant difference between groups. ELM = external limiting membrane, EZ = ellipsoid zone, 
CIZ = cone interdigitation zone.
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survival or death, such as calpain activation. Such activation was found to be a key step in triggering prc to shift 
from survival to death, which peaks 7 days after detachment25.
The duration of macular detachment influences visual outcome greatly, because proapoptotic factors and 
inflammation cytokines become significantly upregulated with increasing duration of separation. Such upregula-
tion leads to more disruption of the EZ and worse BCVA after surgery26,27. In this study, we only included pseu-
dophakic macula-off RRD patients with detachment duration less than 72 hours to avoid time bias and influences 
of lens opacity. This could explain why our visual outcome was better than reported in other reports for patients 
with longer detachment duration. In our study, the mean BCVAs were 74.9 and 72.7 letters in the rasagiline and 
placebo group, respectively, and more than 76% patients achieved a BCVA of 65 letters or better at month 6. In 
a recent study, the final mean BCVA was reported to be merely 62 letters and only 61.1% of the eyes achieved 65 
letters or better after a 24-month recovery after vitrectomy. Although the initial reattachment rate of 94.5% was 
high, their pseudophakic macula-off RRD participants had a long detachment duration of 11 days (range, 3–30 
days)28. Of note, our regression analysis showed that there was no influence on final BCVA whether time before 
presentation was less than 24 hours or between 24 to 72 hours (regression coefficient: −0.320, p = 0.158). With 
respect to visual acuity, previous work has shown that best outcomes were achieved in patients with macular 
detachment of less than 7 days duration. There was no difference between patients with macular detachment of 
0–3 days duration and those with central detachment of 4–7 days1. Our analysis suggests that there was no differ-
ence between patients with less that 24 h macular detachment and those with 2–3 days of macular involvement.
The height of macular detachment was previously reported to influence visual recovery. Lower height of mac-
ular detachment correlates with better visual outcome29,30. This current study observed a consistent negative asso-
ciation between the macular detachment height and the final BCVA, but this trend was not statistically significant 
(regression coefficient: −0.466, p = 0.069).
We achieved a similar SOSR of 70% in pseudophakic macula-off RRD as the rate of 63% reported in an earlier 
study31. However, the primary failure rate was 26% in our study, and was higher than the corresponding rate 
of 10.5% reported in previous reports on pseudophakic RRD14. In the current study, two PVR cases result in a 
PVR rate of 9%, which is rather high but still within the normal range of PVR incidence after RRD surgery cases 
(5–10%)32. Enders et al. studied 2457 patients with RRD and found macular detachment was not only associ-
ated with worse visual outcome but also with a higher recurrent detachment rate33. Therefore, we speculate that 
macula-off status might have contributed to our relatively high failure rate. Recurrent detachment and interven-
tions to treat recurrent detachment have in general a worse final visual outcome than primarily successful cases. 
In our study, 33% of the recurrent detachment cases reached final BCVA of 70 letters or better when the detach-
ment was managed by only one additional surgery. However, no patient achieved this level of visual acuity when 
Univariate analysis Multivariate Analysis
β P value β P value
Preoperative
   Rasagiline treatment −0.77 0.739 — —
   Age −0.353 0.117 — —
   Male gender 0.551 0.010 0.302 0.120
   Time before presentation −0.320 0.158 — —
   Height of macular detachment −0.466 0.069 — —
   Baseline BCVA 0.383 0.087 — —
Postoperative
   Additional surgery −0.410 0.065 — —
   Recurrent detachment −0.282 0.215 — —
   ELM integrity 0.119 0.606 — —
   EZ integrity 0.569 0.007 0.517 0.008
   CIZ integrity 0.143 0.535 — —
   ERM presence 0.009 0.970 — —
   Presence of bulge 0.457 0.037 0.387 0.038
Table 5. Factors influencing final BCVA of the participants in FAS. Height of macular detachment were 
gradable in 16 participants (8 in each group) in the FAS. BCVA = best-corrected visual acuity, ELM = external 
limiting membrane, EZ = ellipsoid zone, CIZ = cone interdigitation zone, ERM = epiretinal membrane.
Rasagiline 
(n = 12)
Placebo 
(n = 11)
Total 
(n = 23) P value
Headache 3 (25%) 2 (18%) 5 (22%) 1
Dyspepsia 0 1 (9%) 1 (4%) —
Rhinitis 1 (8%) 0 1 (4%) —
Joint pain 1 (8%) 0 1 (4%) —
Table 6. Side effects reported by the participants in the safety set.
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more interventions were needed. This finding is in accordance with the data from Enders et al. that the share of 
good BCVA decreased from 16.9% in cases with one recurrence to 7.6% in cases with 2 recurrences and to 0% for 
patients that had 3 interventions33.
We observed significantly increased ELM-RPE thickness during our follow-up. To reveal more details of prc 
restoration, we graded the integrity of the ELM, EZ and CIZ, and noticed significant improvement of integrity of 
ELM and EZ in both the rasagiline and the placebo groups. Our finding is in line with a previous report where 
the prc layer demonstrated a time-dependent thickness increase after successful surgery34. This increase might 
indicate prc regeneration after detachment-induced disruption of prc outer segments, which can be visualized 
on OCT as dropouts of the EZ layer35. Taking a closer look at ELM-RPE thickness, the inner segment, ELM-EZ 
thickness usually achieves fully-restoration at month 6. The outer segment, EZ-RPE thickness, however, stayed 
thinner than that in the healthy fellow eyes after 12-month recovery36. The recovery of EZ-RPE thickness is the 
basis of the reconstitution of the foveal bulge, a sign of favourable foveal configuration36. We observed a foveal 
bulge in 29% of the eyes at month 6, in line with the study from Hasegawa et al., who reported a bulge in 28.6% of 
patients 5–8 months after a macula-off RRD13. Increased EZ-RPE thickness, presence of a foveal bulge and better 
integrity of EZ band indicate good regeneration of prc outer segments and predict better visual outcome36,37. 
Our multiple regression model showed the same result, namely that EZ integrity and presence of foveal bulge are 
factors predicting better BCVA.
There are many limitations to the present study. First, this clinical trial tested a very conservative regimen. 
This might be one major reason for our non-significant results for efficacy of rasagiline. Secondly, the sample size 
is relatively small, which results in low statistical power. Since this was a pilot trial, sample size calculations were 
not rigorous but rather pragmatic. Whitehead et al. suggested a pilot trial sample size per treatment arm of 20 
subjects for small standardized differences (0.1–0.3) to aim for a power of 80% in a subsequent main trial38. In the 
original pilot trial protocol, we planned to enroll 20 patients in each arm. However, the trial was stopped early due 
to slow enrollment, resulting in a sample size of around 10 patients in each arm, which should still be appropriate 
to detect medium standardized differences (0.3–0.7) as suggested in above paper by Whitehead et al.. Thirdly, the 
maximum time of foveal detachment in this study was 96 hours, and we didn’t see any difference in the primary 
outcome. However, this doesn’t mean that one might see a neuroprotective effect in patients with longer waiting 
periods between foveal affection and surgical repair. Since the detachment duration is relevant for the level of prc 
death in RRD, the therapeutic/anti-apoptotic effect of being re-attached may have exceeded that of rasagiline in 
our setting. Hence, the design of the study might just have been inappropriate in this regard. Last but not least, the 
integrity of the outer retinal bands and the presence of a foveal bulge were manually determined, with possible 
bias. Despite these limitations, this study provides some prospective information on the effects of rasagiline as 
pharmacologic adjunct treatment for surgical RRD repair.
conclusion
Perioperative treatment with rasagiline 1 mg/day for 7 days did not show significant benefits for either visual or 
anatomical outcomes 6 months after surgery surgical repair of a macula-off RRD. EZ integrity and the presence 
of a foveal bulge were significant predictors of good final BCVA.
Data availability
The dataset generated and analysed during the current study is available from the corresponding author on 
reasonable request.
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